In the early months of 2026, the global pharmaceutical M&A landscape shifted from a prolonged period of relative caution to a more discernible revival of strategic deal‑making. GSK, Amgen and others restart the pharma M&A engine with a series of targeted acquisitions focused primarily on oncology and immunology, signalling a renewed appetite for science‑driven, portfolio‑balancing transactions rather than large‑scale, generic megamergers. For institutional investors, this marks the beginning of a new M&A cycle in which companies are once again willing to deploy capital to offset patent cliffs, refresh innovation pipelines and consolidate leadership in high‑value therapeutic areas.
The character of these deals reflects a broader industry evolution: the new M&A engine is selective, specialised and closely tied to unmet medical needs. Rather than pursuing size‑for‑size acquisitions, leading players are prioritising assets that can strengthen specific franchises, add unique capabilities or deepen their presence in areas such as immuno‑oncology, targeted protein degraders and respiratory diseases. The 2026 M&A activity also coincides with a broader recalibration of pricing and policy risks, prompting companies to seek assets that can deliver robust returns under tougher regulatory and pricing regimes.
GSK’s 2.2 billion acquisition of Rapt Therapeutics
Among the most visible transactions in which GSK, Amgen and others restart the pharma M&A engine was GSK’s agreement, announced in January 2026, to acquire Rapt Therapeutics for approximately 2.2 billion USD. The deal is structured to provide upfront and contingent consideration, with GSK committing to pay about 10.50 USD per share in cash plus a contingent value right that could increase the total value if certain regulatory and commercial milestones are met.
At the core of the transaction is RAPT‑423, an antibody targeting integrin α4β1, which is being developed for chronic inflammatory diseases such as ulcerative colitis. The molecule is positioned as a potential next‑generation therapy in inflammatory bowel disease and related conditions, with early‑stage data suggesting a differentiated safety and efficacy profile compared with existing biologics. For GSK, the acquisition strengthens its immunology and inflammatory‑disease portfolio, which had already been bolstered by prior investments in biologics and autoimmune therapies.
The strategic logic is clear: GSK is using the Rapt deal to deepen its presence in a high‑value immune‑mediated disease space without over‑extending into unrelated therapeutic areas. The transaction reflects a calculated bet on the long‑term growth of immunology and inflammatory disease markets, which are expected to expand as diagnostic capabilities improve and more patients gain access to specialised therapies in emerging economies. By acquiring RAPT‑423 at a mid‑stage development inflection point, GSK avoids the highest‑risk early‑stage discovery phase while still capturing upside if the asset achieves full approval and commercialisation.
Amgen’s 840 million acquisition of Dark Blue Therapeutics
Parallel to GSK’s move, Amgen restarted its own M&A engine with the acquisition of Dark Blue Therapeutics for up to 840 million USD in January 2026. The deal is front‑loaded, with 400 million USD payable at closing and the remainder dependent on achievement of development, regulatory and commercial milestones, aligning investor and management incentives around the successful advancement of the lead asset.
Dark Blue’s core opportunity lies in targeted protein degraders, a class of molecules that aim to selectively degrade disease‑causing proteins rather than merely inhibiting them. The acquisition brings Amgen a pipeline of pre‑clinical and early‑clinical candidates in oncology, with a particular focus on haematologic malignancies and solid tumours where traditional small‑molecule and antibody‑based approaches have limitations.
For Amgen, the Dark Blue transaction is emblematic of a broader shift toward platform‑level innovation. Rather than acquiring a single, late‑stage asset, the company is investing in a technology platform that can generate multiple candidates across indications, effectively future‑proofing its oncology franchise. The targeted protein‑degrader platform also aligns with the growing interest in modality diversity, where companies seek to combine antibodies, cell therapies, and novel small‑molecule modalities to address the full spectrum of oncology unmet needs.
The broader M&A environment in 2026
The GSK–Rapt and Amgen–Dark Blue deals are not isolated events. They are part of a wider trend identified in 2026 where large pharma companies are cautiously re‑engaging with M&A after a period of relative restraint in 2023 and 2024. The new M&A cycle is characterised by several key features:
- Smaller, more targeted deals: The emphasis is on science‑driven, high‑value assets rather than large‑scale consolidation. Many transactions are in the low‑ to mid‑billion‑dollar range, with a clear focus on specific therapeutic areas rather than broad‑brush portfolio‑overhaul deals.
- Focus on oncology and immunology: These areas continue to attract the bulk of M&A activity, reflecting their strong growth prospects and the high unmet need that justifies premium pricing and investment.
- Broader deal‑making beyond acquisitions: In addition to full‑purchase acquisitions, companies are increasingly engaging in licensing agreements, co‑development deals and joint‑venture structures that allow them to share risk and capital while preserving strategic flexibility.
For the global pharma sector, this broader M&A environment suggests that the 2026 restart is not a return to the megamerger era of the 2010s, but rather a more disciplined, science‑centric re‑engagement with external innovation. The message to small‑ and mid‑cap biotechs is clear: the market is open to deals, but only for assets that can demonstrate clear differentiation, strong clinical data and a viable path to commercialisation under stricter pricing and regulatory frameworks.
Why pricing pressure and patent cliffs are driving M&A
The renewed activity in which GSK, Amgen and others restart the pharma M&A engine is also closely linked to the structural pressures facing the industry. Patent cliffs on blockbuster drugs, combined with increasing pricing pressure from governments and payers, are forcing companies to seek new growth drivers beyond their existing portfolios.
In this context, M&A becomes a key tool for refreshing innovation pipelines and mitigating the risk of revenue decline. By acquiring assets such as RAPT‑423 and Dark Blue’s targeted protein degraders, companies can add molecules that are still in the early stages of clinical evaluation, thereby positioning themselves for the next wave of growth rather than relying solely on legacy products that may soon lose exclusivity.
At the same time, structural pricing pressure is reshaping how companies value and prioritise M&A opportunities. The companies most likely to be acquired are those whose assets are resilient to price cuts, capable of generating strong outcomes‑based evidence, and compatible with value‑based pricing models. This is particularly true in oncology and immunology, where therapies that can demonstrate substantial improvements in survival or quality of life often retain pricing power despite broader industry‑wide cost‑containment trends.
Strategic implications for global pharma
The broader implication of GSK, Amgen and others restart the pharma M&A engine is that the global pharma sector is entering a new phase of strategic realignment. The 2026 M&A cycle is less about pure scale and more about capability‑building, franchise‑strengthening and portfolio‑balancing. Companies that are able to identify and acquire high‑value assets in areas such as oncology, immunology and respiratory diseases will be better positioned to withstand the structural pressures of pricing reform and patent expiry.
For institutional investors, the key takeaway is that M&A is once again a core driver of value creation in the pharma sector. However, the nature of the deals has changed: the focus is on targeted, science‑driven acquisitions that add depth to existing franchises and expand the company’s ability to innovate in high‑growth areas. The 2026 restart also signals that the industry is beginning to adapt to the new pricing environment, with companies using M&A not just to grow revenues, but to build more resilient, diversified portfolios that can thrive in an era of constrained pricing power.
In summary, the 2026 M&A cycle, initiated by the GSK and Amgen acquisitions and extended across the broader pharma sector, represents a strategic pivot toward targeted, science‑driven growth. The restart of the M&A engine is not a return to the megamerger era, but a more disciplined and focused approach to external innovation that reflects the evolving landscape of pricing pressure, patent cliffs, and global demand for high‑value, differentiated therapies.
